CCR Down Under is barely over and we now turn our focus back to Belfast for CCR26, June 10th to 12th, 2026.

Over the rest of December we'll announce the the major trial results to be presented at Titanic Belfast.

Our 8th trial is SAVE-ICU, a multicentre, pragmatic, open-label randomised controlled trial comparing inhaled volatile anaesthetic sedation (isoflurane or sevoflurane) with standard intravenous sedation in mechanically ventilated adults with acute hypoxaemic respiratory failure, including COVID-19 and non-COVID-19 causes. Conducted across ICUs in Canada and the USA, it enrols adults with a PaO₂/FiO₂ ratio ≤300 mm Hg who are expected to remain ventilated and sedated. Patients are randomised 1:1 to inhaled or intravenous sedation delivered using usual-care ICU protocols. The trial uses a hierarchical outcome design developed during the COVID-19 pandemic to allow flexible, efficient evidence generation under resource constraints. The primary outcome is hospital mortality, with secondary outcomes including ventilator-free days, ICU-free days, and quality of life at 3 months. 

Registration for CCR26 opens soon!

Added December 28th